Loading…
Eupraxia Pharmaceuticals Inc. is projected to rise to $8.48 by 2027, a +27% move from its current price of $6.68. EPRX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $6.52 | $6.68 | $6.85 | +0.06% |
| Jul 14 | $6.46 | $6.69 | $6.92 | +0.12% |
| Jul 15 | $6.41 | $6.69 | $6.98 | +0.18% |
| Jul 16 | $6.37 | $6.70 | $7.03 | +0.24% |
| Jul 17 | $6.34 | $6.70 | $7.08 | +0.30% |
| Jul 18 | $6.31 | $6.70 | $7.12 | +0.36% |
| Jul 19 | $6.29 | $6.71 | $7.16 | +0.43% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.29 | $6.71 | $7.16 | +0.43% |
| Week 2 | $6.14 | $6.74 | $7.39 | +0.85% |
| Week 3 | $6.04 | $6.77 | $7.57 | +1.28% |
| Week 4 | $5.97 | $6.79 | $7.74 | +1.71% |
| Week 5 | $5.90 | $6.82 | $7.89 | +2.15% |
| Week 6 | $5.84 | $6.85 | $8.04 | +2.58% |
| Week 7 | $5.79 | $6.88 | $8.17 | +3.02% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.
The company’s portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc.
in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Eupraxia Pharmaceuticals Inc. (EPRX) is a healthcare company with a current price of $6.69 and a market capitalization of $437.04M, ranking 3181. The stock sits in a defined price landscape with a bullish near-term sentiment and a probabilistic path higher over the coming years.
Near-term outlook is supported by a forecast series that shows the average price rising from the 2026 level of $6.69 to progressively higher targets, with a long-run average price of $50.46 anticipated by 2050 and a long-run upside implied by a 654.3% ROI in 2050. The sequence of yearly averages and ROIs suggests a sustained bullish tilt across the latter half of the period, albeit with varying degrees of annual upside.
A major floor 22.2% below — a decisive break under it would weaken the trend.
The nearest floor, 11.4% below — buyers have tended to step in here.
The nearest ceiling, 10.5% above — a clean break opens room to run.
A major ceiling 22.5% above — clearing it would confirm fresh momentum.
Key EPRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EPRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.74 | Sell | $6.75 | Sell |
| MA 10 | $6.69 | Sell | $6.68 | Buy |
| MA 20 | $6.48 | Buy | $6.61 | Buy |
| MA 50 | $6.78 | Sell | $6.74 | Sell |
| MA 100 | $7.13 | Sell | $6.90 | Sell |
| MA 200 | $6.97 | Sell | $6.66 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.65 | Neutral |
| Stoch RSI (14) | 52.57 | Neutral |
| CCI (20) | 59.51 | Neutral |
| Williams %R (14) | -35.82 | Info |
| MACD (12,26,9) | 0.06 | Buy |
| ROC (12) | 4.54 | Buy |
| Bollinger %B (20,2) | 0.69 | Neutral |
| Stochastic %K (14) | 64.18 | Neutral |
| TRIX (15) | -0.07 | Sell |
| Awesome (5,34) | 0.18 | Buy |
| Ultimate (7,14,28) | 53.00 | Neutral |
| Momentum (10) | 0.27 | Buy |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 6.86 | Sell |
| ADX (14) | 10.24 | Neutral |
| ATR (14) | 0.15 | Info |
The 30-day technical picture is bullish, with RSI(14) at 50 and near-term momentum supported by key moving averages. The SMA50 is $6.83, the SMA200 is $6.95, indicating the price is hovering around the short- and medium-term trend lines.
In the very near term, the stock trades within a 30-day range of $5.67 to $7.90, displaying a modestly elevated volatility level. Support is posted near $5.92 and resistance near $7.53, providing defined levels for tactical positioning and risk management.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.92 | $6.68 | $8.98 | 0% | Neutral | |
| $6.81 | $8.48 | $11.12 | +27% | Bullish | |
| $6.80 | $8.68 | $11.78 | +30% | Bullish | |
| $7.46 | $9.71 | $13.54 | +45% | Bullish | |
| $7.89 | $10.46 | $14.91 | +57% | Bullish | |
| $8.13 | $10.97 | $15.94 | +64% | Bullish | |
| $10.13 | $13.87 | $20.52 | +108% | Bullish | |
| $11.45 | $15.90 | $23.90 | +138% | Bullish | |
| $11.78 | $16.59 | $25.29 | +148% | Bullish | |
| $12.00 | $17.12 | $26.46 | +156% | Bullish | |
| $18.05 | $27.29 | $44.67 | +308% | Bullish | |
| $29.58 | $49.41 | $87.97 | +640% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $5.92 | $6.68 | $7.97 | +0.00% |
| August 2026 | $5.75 | $6.76 | $8.16 | +1.25% |
| September 2026 | $5.96 | $7.06 | $8.61 | +4.39% |
| October 2026 | $6.10 | $7.27 | $8.94 | +2.95% |
| November 2026 | $6.01 | $7.19 | $8.90 | -1.10% |
| December 2026 | $6.00 | $7.21 | $8.98 | +0.24% |
Click any year to see its month-by-month EPRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect EPRX to range from $5.92 to $8.98 through 2026. The $6.68 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The EPRX price prediction for 2027 points to an average of $8.48 (low $6.81, high $11.12) — a potential gain of +27% on today's $6.68. Buyers look set to stay in control over this stretch.
In 2028, EPRX is projected to trade between $6.80 and $11.78, averaging $8.68 — a potential gain of +30% from today's $6.68. That is up +2% on the projected 2027 average. Momentum favours further upside here.
Eupraxia Pharmaceuticals Inc.'s 2029 outlook centres on $9.71, within a $7.46 to $13.54 range. That is up +12% on the projected 2028 average. That marks a +45% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, EPRX could reach as high as $14.91, with a base case around $10.46 and support toward $7.89 — roughly +57% from $6.68. Momentum favours further upside here.
Expect EPRX to range from $8.13 to $15.94 through 2031. The $10.97 average target implies a +64% move from current prices. That is up +5% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The EPRX price prediction for 2032 points to an average of $13.87 (low $10.13, high $20.52) — a potential gain of +108% on today's $6.68. Momentum favours further upside here.
In 2033, EPRX is projected to trade between $11.45 and $23.90, averaging $15.90 — a potential gain of +138% from today's $6.68. That is up +15% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Eupraxia Pharmaceuticals Inc.'s 2034 outlook centres on $16.59, within a $11.78 to $25.29 range. That is up +4% on the projected 2033 average. That marks a +148% change versus current levels. Momentum favours further upside here.
By 2035, EPRX could reach as high as $26.46, with a base case around $17.12 and support toward $12.00 — roughly +156% from $6.68. Buyers look set to stay in control over this stretch.
Expect EPRX to range from $18.05 to $44.67 through 2040. The $27.29 average target implies a +308% move from current prices. That is up +59% on the projected 2035 average. Momentum favours further upside here.
The EPRX price prediction for 2050 points to an average of $49.41 (low $29.58, high $87.97) — a potential gain of +640% on today's $6.68. Buyers look set to stay in control over this stretch.
Investing $1,000 in EPRX today (≈ 149.700599 EPRX) could be worth
$7,397.44
+$6,397.44 (+640%) by 2050 · US Dollar
Based on the average projected EPRX price of $49.41 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EPRXwould be worth at today's price.
$1,000 invested in EPRX on Jul 10, 2025 (≈ 177.967611 EPRX) would be worth
$1,188.82
+$188.82 (+18.9%) today · 1.19× · US Dollar
Based on a EPRX entry price of $5.62 vs. today's $6.68.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.69 | $998.51 | -0.1% |
| 1 month ago | $5.92 | $1,128.38 | +12.8% |
| 3 months ago | $6.86 | $973.76 | -2.6% |
| 6 months ago | $8.2 | $814.63 | -18.5% |
| 1 year ago | $5.62 | $1,188.82 | +18.9% |
| All time (2.3y) ago | $2.95 | $2,264.41 | +126.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EPRX forecast.
Our base-case forecast reaches $13.00 around 2032.
Implied market cap at $13.00: $849.25M
The multi-year forecast shows a progressive upside with notable milestones. In 2026, the min price is $5.92, the avg is $6.69, the max is $9.08, and the ROI is 0 with a neutral sentiment. By 2027, the avg rises to $8.53 with a 27.4% ROI and a bullish sentiment, followed by 2028 at $8.69 (29.9% ROI) and 2029 at $9.82 (46.8% ROI).
The trajectory continues to 2030 with an avg of $10.53 and a 57.4% ROI, and 2031 at $10.97 with a 63.9% ROI. By 2032, the avg is $14.16 (111.7% ROI) and the max reaches $21.05 under a bullish framework. In 2033 the avg is $16.12 (142.0% ROI), and 2034-2035 show continued gains (2034 avg $16.62, 148.4% ROI; 2035 avg $17.40, 160.1% ROI).
The forecast accelerates after 2035, with 2040 posting an avg of $27.59 and a 312.4% ROI, and 2050 showing an avg of $50.46 with a 654.3% ROI. This long-run picture underlines a clear bullish trend, but the figures are estimates and carry the usual uncertainties associated with biotechnology companies and regulatory outcomes.
Tap a question to reveal the answer.
Avg price $10.53; min $7.91; max $15.07; ROI 57.4%; sentiment bullish.
Forecasts show rising averages across years with significant ROIs in later years (e.g., 2030 ROI 57.4%, 2040 ROI 312.4%, 2050 ROI 654.3%), and a bullish sentiment from 2027 onward, noting these are estimates and not guarantees.
Yes. The 2032 forecast shows a max of $21.05 and an avg of $14.16, with min $10.30, indicating a potential move above $20 in that year.
Current price $6.69; market cap $437.04M; rank 3181.
Sentiment is BULLISH; RSI(14) is 50. The 50-day SMA is $6.83 and the 200-day SMA is $6.95. The 30-day price range is $5.67-$7.90 with support at $5.92 and resistance at $7.53.
Eupraxia Pharmaceuticals Inc. Community Discussion
0Share your Eupraxia Pharmaceuticals Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.